- Home
- PBFS vs ETON Comparison
PBFS vs ETON Comparison
Compare PBFS & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PBFS | ETON |
|---|---|---|
| Founded | 1889 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 329.3M | 498.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | PBFS | ETON |
|---|---|---|
| Price | $14.52 | $15.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $29.67 |
| AVG Volume (30 Days) | 12.4K | ★ 277.8K |
| Earning Date | 01-29-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.64 | N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $91,717,000.00 | $70,316,000.00 |
| Revenue This Year | N/A | $113.27 |
| Revenue Next Year | N/A | $36.70 |
| P/E Ratio | $17.52 | ★ N/A |
| Revenue Growth | 17.04 | ★ 102.77 |
| 52 Week Low | $10.60 | $11.09 |
| 52 Week High | $14.93 | $23.00 |
Technical Indicators
Market Signals| Indicator | PBFS | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 70.90 | 40.84 |
| Support Level | $13.05 | $16.13 |
| Resistance Level | $13.49 | $17.19 |
| Average True Range (ATR) | 0.27 | 0.75 |
| MACD | 0.13 | 0.10 |
| Stochastic Oscillator | 76.63 | 29.84 |
Price Performance
Historical ComparisonAbout PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.